Table 2.
Complete and partial clearance of AKs in the study subjects
| Variable | Calcipotriol + 5-FU n/Total n (%) | Vaseline + 5-FU n/Total n (%) | P-Value | Difference (95% CI) |
|---|---|---|---|---|
| Complete clearance | ||||
| All locations | 66/107 (62) | 9/111 (8) | <0.0001 | 54 (42–63) |
| Forehead | 26/37 (70) | 1/27 (4) | <0.0001 | 66 (44–78) |
| Temples | 13/18 (72) | 3/23 (13) | 0.0001 | 59 (29–77) |
| Cheek | 8/11 (73) | 3/19 (16) | 0.0022 | 57 (20–77) |
| Scalp | 15/25 (60) | 2/25 (8) | 0.0001 | 52 (26–70) |
| Forearm | 4/16 (25) | 0/17 (0) | 0.0301 | 25 (1–49) |
| Partial clearance | ||||
| All locations | 88/107 (82) | 12/111 (11) | <0.0001 | 71 (60–79) |
| Forehead | 35/37 (95) | 2/27 (7) | <0.0001 | 88 (68–94) |
| Temples | 18/18 (100) | 3/23 (13) | <0.0001 | 87 (61–95) |
| Cheek | 9/11 (82) | 3/19 (16) | 0.0005 | 66 (29–83) |
| Scalp | 17/25 (68) | 4/25 (16) | 0.0002 | 52 (25–70) |
| Forearm | 9/16 (56) | 0/17 (0) | 0.0004 | 56 (22–81) |
Abbreviations: 5-FU, 5-fluorouracil; AK, actinic keratosis; CI, confidence interval.
Complete clearance was defined as 100% reduction and partial clearance as at least 75% reduction in the number of AKs in the treated anatomical site at 8 weeks after treatment.